CODEX+ CELIDA Recommendations
1.5.2 - ci-build
CODEX+ CELIDA Recommendations
1.5.2 - ci-build
CODEX+ CELIDA Recommendations - Local Development build (v1.5.2) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
Contents:
This page provides a list of the FHIR artifacts defined as part of this implementation guide.
These define activities that can be performed as part of content in this implementation guide.
| Abdominal Positioning |
In ARDS and a PaO2/FiO2 < 150 mmHg, abdominal positioning should be consistently performed, with an abdominal positioning interval of at least 16 hours. |
| Antithrombotic prophylaxis with Certoparin |
Antithrombotic prophylaxis with Certoparin in hospitalised COVID-19 patients (in absence of contraindications for LWMH) |
| Antithrombotic prophylaxis with Dalteparin |
Antithrombotic prophylaxis with Dalteparin in hospitalised COVID-19 patients (in absence of contraindications for LWMH) |
| Antithrombotic prophylaxis with Enoxaparin |
Antithrombotic prophylaxis with Enoxaparin in hospitalised COVID-19 patients (in absence of contraindications for LWMH) |
| Antithrombotic prophylaxis with Fondaparinux |
Antithrombotic prophylaxis with Fondaparinux in hospitalised COVID-19 patients (when contraindications for LWMH exist) |
| Antithrombotic prophylaxis with Nadroparin |
Antithrombotic prophylaxis with Nadroparin in hospitalised COVID-19 patients (in absence of contraindications for LWMH) |
| Antithrombotic prophylaxis with Tinzaparin |
Antithrombotic prophylaxis with Tinzaparin in hospitalised COVID-19 patients |
| NO Therapeutic Anticoagulation Treatment with Fondaparinux |
No Therapeutic Anticoagulation Treatment with Fondaparinux for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism) |
| No Therapeutic Anticoagulation Treatment with Argatroban |
No Therapeutic Anticoagulation Treatment with Argatroban for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism) |
| No Therapeutic Anticoagulation Treatment with Certoparin |
No Therapeutic Anticoagulation Treatment with Certoparin for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism) |
| No Therapeutic Anticoagulation Treatment with Dalteparin |
No Therapeutic Anticoagulation Treatment with Dalteparin for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism) |
| No Therapeutic Anticoagulation Treatment with Dalteparin |
No Therapeutic Anticoagulation Treatment with Dalteparin for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism) |
| No Therapeutic Anticoagulation Treatment with Dalteparin |
No Therapeutic Anticoagulation Treatment with Dalteparin for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism) |
| No Therapeutic Anticoagulation Treatment with Enoxaparin |
No Therapeutic Anticoagulation Treatment with Enoxaparin for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism) |
| No Therapeutic Anticoagulation Treatment with Enoxaparin |
No Therapeutic Anticoagulation Treatment with Enoxaparin for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism) |
| No Therapeutic Anticoagulation Treatment with Nadroparin |
No Therapeutic Anticoagulation Treatment with Nadroparin for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism) |
| No Therapeutic Anticoagulation Treatment with Tinzaparin |
No Therapeutic Anticoagulation Treatment with Tinzaparin for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism) |
| No Therapeutic Anticoagulation Treatment with UFH |
No Therapeutic Anticoagulation Treatment with UFH for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism) |
| Prophylactic Anticoagulation Treatment with UFH subcutaneous |
Prophylactic Treatment with UFH subcutaneous for non-intensive care hospitalised COVID-19 patients |
| Therapeutic Anticoagulation Treatment UFH |
Therapeutic Anticoagulation Treatment (UFH) for non-intensive care hospitalised COVID-19 patients patients with high risk (D-Dimer >= 2mg/l) |
| Therapeutic Anticoagulation Treatment with Argatroban |
Therapeutic Anticoagulation Treatment with Argatroban for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism) |
| Therapeutic Anticoagulation Treatment with Certoparin |
Therapeutic Anticoagulation Treatment (NMH) for non-intensive care hospitalised COVID-19 patients patients with high risk (D-Dimer >= 2mg/l) with Certoparin |
| Therapeutic Anticoagulation Treatment with Dalteparin |
Therapeutic Anticoagulation Treatment (NMH) for non-intensive care hospitalised COVID-19 patients patients with high risk (D-Dimer >= 2mg/l) with Dalteparin |
| Therapeutic Anticoagulation Treatment with Dalteparin |
Therapeutic Anticoagulation Treatment (NMH) for non-intensive care hospitalised COVID-19 patients patients with high risk (D-Dimer >= 2mg/l) with Dalteparin |
| Therapeutic Anticoagulation Treatment with Dalteparin |
Therapeutic Anticoagulation Treatment (NMH) for non-intensive care hospitalised COVID-19 patients patients with high risk (D-Dimer >= 2mg/l) with Dalteparin |
| Therapeutic Anticoagulation Treatment with Enoxaparin |
Therapeutic Anticoagulation Treatment (NMH) for non-intensive care hospitalised COVID-19 patients patients with high risk (D-Dimer >= 2mg/l) with Enoxaparin |
| Therapeutic Anticoagulation Treatment with Enoxaparin |
Therapeutic Anticoagulation Treatment (NMH) for non-intensive care hospitalised COVID-19 patients patients with high risk (D-Dimer >= 2mg/l) with Enoxaparin |
| Therapeutic Anticoagulation Treatment with Fondaparinux |
Therapeutic Anticoagulation Treatment with Fondaparinux for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism) |
| Therapeutic Anticoagulation Treatment with Nadroparin |
Therapeutic Anticoagulation Treatment (NMH) for non-intensive care hospitalised COVID-19 patientswith high risk (D-Dimer >= 2mg/l) with Nadroparin |
| Therapeutic Anticoagulation Treatment with Tinzaparin |
Therapeutic Anticoagulation Treatment (NMH) for non-intensive care hospitalised COVID-19 patients patients with high risk (D-Dimer >= 2mg/l) with Tinzaparin |
These define workflows, rules, strategies, or protocols as part of content in this implementation guide.
| Abdominal positioning for ventilated patients with ARDS and a PaO2/FiO2 < 150 mmHg |
Abdominal positioning for ventilated patients with ARDS and a PaO2/FiO2 < 150 mmHg |
| Abdominal positioning plan in case of ARDS and a PaO2/FiO2 < 150 mmHg |
In ARDS and a PaO2/FiO2 < 150 mmHg, abdominal positioning should be consistently performed, with an abdominal positioning interval of at least 16 hours. |
| Anticoagulation Plan for hospitalized intensive-care COVID-19 patients with no specific indication |
In intensive care patients without a specific indication (e.g. pulmonary embolism), therapeutic anticoagulation should not be given. |
| Antithrombotic prophylaxis with Fondaparinux |
Antithrombotic prophylaxis with Fondaparinux in hospitalised COVID-19 patients |
| Antithrombotic prophylaxis with LWMH |
Hospitalized patients with COVID-19 should receive standard drug thromboembolism prophylaxis with low molecular weight heparin in the absence of contraindications. Alternatively, fondaparinux may be used. |
| No therapeutic anticoagulation for intensive care COVID-19 patients with no specific indication |
No therapeutic anticoagulation for intensive care COVID-19 patients with no specific indication |
| PEEP Intervention Plan for Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.0 |
PEEP Intervention Plan for Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.0 - 0.39 |
| PEEP Intervention Plan for Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.4 |
PEEP Intervention Plan for Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 043 - 0.49 |
| PEEP Intervention Plan for Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.5 |
PEEP Intervention Plan for Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.5 - 0.59 |
| PEEP Intervention Plan for Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.6 |
PEEP Intervention Plan for Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.6 - 0.69 |
| PEEP Intervention Plan for Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.7 |
PEEP Intervention Plan for Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.7 - 0.79 |
| PEEP Intervention Plan for Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.8 |
PEEP Intervention Plan for Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.8 - 0.89 |
| PEEP Intervention Plan for Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.9 |
PEEP Intervention Plan for Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.9 - 0.99 |
| PEEP Intervention Plan for Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 1.0 |
PEEP Intervention Plan for Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 1.0 - 1.09 |
| PEEP for ventilated COVID-19 patients |
PEEP for ventilated COVID-19 patients |
| Prophylactic anticoagulation in hospitalized COVID-19 patients |
Prophylactic anticoagulation in hospitalized COVID-19 patients |
| Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients with no renal function impairment (eGFR >= 30ml/min)) |
In hospitalized, non-intensive care patients with COVID-19 and increased risk (e.g., D-dimers ≥ 2 mg/l), therapeutic anticoagulation can be considered if the risk of bleeding is low. Anticoagulation, preferentially with NMH or UFH, can be considered. |
| Therapeutic anticoagulation in non-intensive care, high-risk COVID-19 patients |
Therapeutic anticoagulation in non-intensive care, high-risk COVID-19 patients |
| Tidal volume / end-inspiratory airway pressure for ventilated COVID-19 patients with ARDS |
Tidal volume / end-inspiratory airway pressure for ventilated COVID-19 patients with ARDS |
| Tidal volume for ventilated patients with ARDS |
Tidal volume for ventilated patients with ARDS |
| Ventilation Plan for COVID-19 patients with ARDS |
In ventilated patients with COVID-19 and ARDS, tidal volume should be ≤ 6 ml/kg standard body weight, end-inspiratory airway pressure ≤ 30 cm H2O. |
| Ventilation Plan for patients with ARDS |
We recommend ventilating patients with ARDS with a VT ≤ 6 ml/kg standard body weight (bw). (Table 1, Appendix) |
These define new code systems used by systems conforming to this implementation guide.
| CODEX-CELIDA |
Concepts required in recommendations that are not defined elsewhere |
| KontaktArtDe |
Klassifizierung eines Kontaktes mit einer Gesundheitseinrichtung |
These are resources that are used within this implementation guide that do not fit into one of the other categories.
| Hospitalised COVID-19 patients, treated on ICU, without thrombembolic complication |
Hospitalised COVID-19 patients, treated on ICU, without thrombembolic complication |
| Population: Hospitalised COVID-19 patients with existing contraindications to LWMH |
Population for recommendation 15: Hospitalised COVID-19 patients with existing contraindications to LWMH |
| Population: Hospitalised COVID-19 patients without contraindications to LWMH |
Population for recommendation 15: Hospitalised COVID-19 patients without contraindications to LWMH |
| Population: Hospitalised COVID-19 patients without the need for intensive care therapy considered high-risk for developing venous thrombosis |
Population for recommendation 17 from guideline from https://www.awmf.org/leitlinien/detail/ll/113-001LG.html with characteristics: without the need for intensive care therapy, considered high-risk for developing venous thrombosis |
| Population: Ventilated COVID-19 Patients with ARDS |
Ventilated COVID-19 patients with ARDS |
| Population: Ventilated COVID-19 Patients with severe ARDS |
Ventilated COVID-19 patients with severe ARDS, defined by oxygenation failure (Horovitz Quotient lower than 150) |
| Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.0 |
Ventilated COVID-19 patients, inspiratory oxygen fraction currently 0.0 - 0.39 |
| Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.4 |
Ventilated COVID-19 patients, inspiratory oxygen fraction currently 0.4 - 0.49 |
| Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.5 |
Ventilated COVID-19 patients, inspiratory oxygen fraction currently 0.5 - 0.59 |
| Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.6 |
Ventilated COVID-19 patients, inspiratory oxygen fraction currently 0.6 - 0.69 |
| Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.7 |
Ventilated COVID-19 patients, inspiratory oxygen fraction currently 0.7 - 0.79 |
| Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.8 |
Ventilated COVID-19 patients, inspiratory oxygen fraction currently 0.8 - 0.89 |
| Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.9 |
Ventilated COVID-19 patients, inspiratory oxygen fraction currently 0.9 - 0.99 |
| Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 1.0 |
Ventilated COVID-19 patients, inspiratory oxygen fraction currently 1.0 |
| Population: Ventilated patients with ARDS |
Patients with ARDS |
IG © 2021+ Universitätsmedizin Greifswald. Package recommendations.celida.codex.netzwerk-universitaetsmedizin.de#1.5.2 based on FHIR 5.0.0. Generated 2024-08-07
Links: Table of Contents |
QA Report |
Issues |
Submit an issue |
Version History |
|